Skip to content

Effect of Long-term Exercise on Haemostasis and Inflammation in Patients With Coronary Artery Disease

Effect of Long-term Exercise on Haemostasis and Inflammation Compared With Standard Care in Patients With Stable Coronary Artery Disease: a Randomised Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04268992
Enrollment
142
Registered
2020-02-13
Start date
2020-07-03
Completion date
2023-01-16
Last updated
2023-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Exercise, Hemostasis, Inflammation

Keywords

Cardiovascular Diseases, Exercise, Hemostasis, Inflammation

Brief summary

Introduction: Regular exercise training improves prognosis in patients with coronary artery disease (CAD). This study investigates whether the beneficial effects of exercise can be partly explained by favourable changes in haemostasis and inflammation. Methods: 150 CAD patients are randomised to a supervised long-term exercise program (3 months) or usual care. Blood samples are obtained at baseline, 1.5 months, and 3 months after randomisation. Results: The investigators will evaluate platelet turnover and aggregation, coagulation, fibrinolysis, and inflammatory markers before and after short- and long-term exercise, and the two randomised groups will be compared. Perspectives: The present study will increase our knowledge of the beneficial mechanisms underlying the effect of exercise in CAD patients, potentially paving the way for improved exercise recommendations.

Interventions

OTHERLong-term exercise

All patients randomised to long-term exercise will perform exercise training at least three times a week for three months. The exercise is supervised and individualised.

Sponsors

National Hospital of the Faroe Islands
CollaboratorOTHER_GOV
Aarhus University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

A randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Angiographically verified coronary artery disease with stenosis of at least 50% or previous percutaneous coronary intervention (PCI)/coronary artery bypass graft (CABG) surgery. * Diagnosis or revascularisation have been made at least 12 months prior to inclusion.

Exclusion criteria

* Inability to perform strenuous exercise * Anticoagulant treatment * Heart failure (ejection fraction \<30% or NYHA \>2) * Implanted implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) * Serious arrhythmia requiring hospitalisation within the last 6 months * Severe valvular heart disease * Chronic obstructive pulmonary disease GOLD IV

Design outcomes

Primary

MeasureTime frameDescription
Changes in clot lysis time using the clot lysis assay.3 monthsChanges in clot lysis time in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare clot lysis time assessed at baseline and after three months of supervised exercise for every patient.
Changes in clot maximum absorbance using the clot lysis assay.3 monthsChanges in maximum absorbance in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare clot maximum absorbance assessed at baseline and after three months of supervised exercise for every patient.
Changes in area under the curve using the clot lysis assay.3 monthsChanges in area under the curve in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare area under the curve assessed at baseline and after three months of supervised exercise for every patient.
Changes in fibrinolytic biomarkers: tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1).3 monthsChanges in fibrinolytic biomarkers in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare fibrinolytic biomarkers assessed at baseline and after three months of supervised exercise for every patient.

Secondary

MeasureTime frameDescription
Changes in thrombin generation assessing lag-time until initial thrombin generation.3 monthsChanges in lag-time until initial thrombin generation in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare the results assessed at baseline and after three months of supervised exercise for every patient.
Changes in thrombin generation assessing time to peak.3 monthsChanges in time to peak in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare the results assessed at baseline and after three months of supervised exercise for every patient.
Changes in thrombin generation assessing endogenous thrombin potential.3 monthsChanges in endogenous thrombin potential in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare the results assessed at baseline and after three months of supervised exercise for every patient.
Changes in coagulation biomarkers: APTT, INR, Factor VIII, vWF.3 monthsChanges in coagulation biomarkers in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare coagulation biomarkers assessed at baseline and after three months of supervised exercise for every patient.
Changes in inflammatory biomarkers: CRP, multiple interleukins, tumor necrosis factor alpha (TNF-α), interferon gamma (INF-γ) and more.3 monthsChanges in inflammatory biomarkers in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare inflammatory biomarkers assessed at baseline and after three months of supervised exercise for every patient.
Changes in thrombin generation assessing maximum concentration of thrombin.3 monthsChanges in maximum concentration of thrombin in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare the results assessed at baseline and after three months of supervised exercise for every patient.
Changes in platelet aggregation using arachidonic acid (ASPI) as agonist.3 monthsChanges in platelet aggregation with ASPI as agonist in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare the results assessed at baseline and after three months of supervised exercise for every patient.
Changes in platelet aggregation using adenosine diphosphate (ADP) as agonist.3 monthsChanges in platelet aggregation with ADP as agonist in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare the results assessed at baseline and after three months of supervised exercise for every patient.
Changes in platelet aggregation using thrombin receptor activating peptide-6 (TRAP) as agonist.3 monthsChanges in platelet aggregation with TRAP as agonist in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group). Moreover, the investigators will compare the results assessed at baseline and after three months of supervised exercise for every patient.

Other

MeasureTime frameDescription
Changes in cardiorespiratory performance: maximal oxygen uptake3 monthsChanges in maximal oxygen uptake in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group).
Incidence of adverse events associated with the exercise intervention.3 monthsNumber of adverse events (severe, moderate or mild) and training related injuries in coronary artery disease patients who are randomised to long-term exercise.
Changes in physical health and mental health (quality of life) assessed by the SF-36v2 questionnaire.3 monthsChanges in physical and mental health in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group).
Changes in cardiorespiratory performance: maximal power output3 monthsChanges in maximal power output in coronary artery disease patients who are randomised to long-term exercise compared with patients randomised to usual care (control group).

Countries

Faroe Islands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026